Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chubb
Covington
Argus Health
Julphar
Cantor Fitzgerald
McKesson
Fish and Richardson
Mallinckrodt

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

« Back to Dashboard

Clinical Trials for Lansoprazole, Amoxicillin And Clarithromycin

Trial ID Title Status Sponsor Phase Summary
NCT00149084 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Yokoyama Foundation for Clinical Pharmacology Phase 3 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00149084 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Hamamatsu University Phase 3 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00281047 The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy Unknown status Oita University Phase 2/Phase 3 FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
NCT00281047 The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy Unknown status Hamamatsu University Phase 2/Phase 3 FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
NCT00816140 Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication Completed National Taiwan University Hospital Phase 4 Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter pylori eradication. However, because of unsatisfactory eradication rate (80-85%), the Maastricht III guideline recommended extending the treatment duration to increase the eradication rate. Recently, levofloxacin (500 mg qd)-based triple therapy has been shown to achieve an eradication rate of 90% for both the first- and second-line treatment for H. pylori eradication. Several studies have demonstrated that high dose (750mg) and short-course (5 days) levofloxacin is as effective and well tolerated as traditional dose (500mg) and course (10 days) for treatment of mild-to-severe community acquired pneumonia. The high dose and short-course therapy has the potential to increase patient compliance and reduce bacterial resistance to fluoroquinolones. However, whether increasing the dosage of levofloxacin from 500mg to 750 mg qd can augment the efficacy of triple therapy in eradication of H. pylori and shorten the duration of therapy remains unknown. Although levofloxacin-based regimen was presumed to be more effective, previous reports pointed the concern that resistance to fluoroquinolone and other antibiotics which susceptible to the pumping efflux of bacteriae would increase among the gut flora.
NCT01061437 S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori) Completed Bill and Melinda Gates Foundation Phase 3 The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lansoprazole, Amoxicillin And Clarithromycin

Condition Name

Condition Name for Lansoprazole, Amoxicillin And Clarithromycin
Intervention Trials
Helicobacter Pylori Infection 5
Dyspepsia 2
Helicobacter Infections 2
Gastritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lansoprazole, Amoxicillin And Clarithromycin
Intervention Trials
Helicobacter Infections 8
Communicable Diseases 4
Infection 4
Gastritis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lansoprazole, Amoxicillin And Clarithromycin

Trials by Country

Trials by Country for Lansoprazole, Amoxicillin And Clarithromycin
Location Trials
Japan 20
Taiwan 4
Korea, Republic of 3
Mexico 2
Honduras 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lansoprazole, Amoxicillin And Clarithromycin

Clinical Trial Phase

Clinical Trial Phase for Lansoprazole, Amoxicillin And Clarithromycin
Clinical Trial Phase Trials
Phase 4 8
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lansoprazole, Amoxicillin And Clarithromycin
Clinical Trial Phase Trials
Completed 7
Recruiting 5
Unknown status 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lansoprazole, Amoxicillin And Clarithromycin

Sponsor Name

Sponsor Name for Lansoprazole, Amoxicillin And Clarithromycin
Sponsor Trials
National Taiwan University Hospital 3
Hamamatsu University 2
CJ HealthCare Corporation 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lansoprazole, Amoxicillin And Clarithromycin
Sponsor Trials
Other 19
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
Fish and Richardson
Covington
US Army
Chubb
McKinsey
Teva
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.